Regulatory Scrutiny and Compliance Risks
This theme has appeared in 1 daily market analyses, first identified on Jan 10, 2026, most recently on Jan 10, 2026.
Every Mention of This Trend
Jan 10, 2026
M&A deals face increased anti-trust scrutiny, while select firms confront compliance and listing challenges.
Supporting data: FTC blocks Edwards Lifesciences/JenaValve deal; FAT Brands receives multiple Nasdaq non-compliance notices.